Zoetis Inc. $ZTS Position Reduced by Lido Advisors LLC

Lido Advisors LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 37.0% during the fourth quarter, HoldingsChannel reports. The fund owned 29,871 shares of the company’s stock after selling 17,549 shares during the quarter. Lido Advisors LLC’s holdings in Zoetis were worth $3,758,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Nordea Investment Management AB boosted its holdings in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the period. Seilern Investment Management Ltd raised its position in Zoetis by 361.2% during the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after acquiring an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Zoetis by 134.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after acquiring an additional 935,432 shares in the last quarter. Pincus Capital Management LP bought a new position in Zoetis during the fourth quarter valued at approximately $2,109,000. Finally, Prudential PLC raised its position in Zoetis by 17.7% during the third quarter. Prudential PLC now owns 197,852 shares of the company’s stock valued at $28,950,000 after acquiring an additional 29,702 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 0.1%

ZTS opened at $79.49 on Monday. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $171.52. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm’s fifty day moving average price is $100.52 and its two-hundred day moving average price is $115.52. The company has a market capitalization of $33.33 billion, a P/E ratio of 13.18, a P/E/G ratio of 1.24 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Insiders Place Their Bets

In related news, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 11,650 shares of company stock valued at $886,384 in the last 90 days. 0.22% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent research reports. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Bank of America lifted their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Finally, Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $133.92.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis published the company’s 2025 Sustainability Report, highlighting progress in animal health and its next phase of sustainability goals. Zoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better Future
• Neutral Sentiment: The stock saw unusual call-option buying, suggesting some traders are positioning for a rebound despite the recent selloff. Zoetis (ZTS) rises as investors refocus on outlook and precision-animal-health expansion
• Neutral Sentiment: Zoetis’ valuation is being reassessed after its guidance cut and ongoing concerns about companion-animal demand and legal issues. A Look At Zoetis (ZTS) Valuation After Guidance Cut Legal Actions And Companion Animal Headwinds
• Negative Sentiment: Jim Cramer said he prefers Elanco over Zoetis, adding to negative investor sentiment around ZTS. Jim Cramer Recommends Elanco Over Zoetis
• Negative Sentiment: Multiple law firms announced or promoted class-action lawsuits against Zoetis, with allegations tied to alleged misleading statements, FDA safety warnings, and market-share erosion. ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: The company is also facing investor-notice deadlines and additional securities-fraud claims, keeping legal overhang front and center for shareholders. INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. (ZTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.